Plateforme NeuroTimone (PFNT)

La PFNT (Plateforme NeuroTimone) est un ensemble cohérent d'outils d'exploration en neurobiologie permettant des investigations aux échelles moléculaires, cellulaires et intégrées.

A la Une

  1. GlioME Team: another new paper in Cell Death & Disease!

    A new article from the GlioME Team has just been published in Cell Death and Disease: SMAC mimetic drives microglia phenotype and glioblastoma immune microenvironment.

  2. GlioME team and PETRA"TECH" platform: a new paper is out in Neuro-Oncology!

    Because generation of patient avatar for preclinical therapeutic development is critically needed in neuro-oncology, the GlioME team in collaboration with the PETRA"TECH" platform developed an easy method to generate tumoroids from primary and metastatic brain tumors, including a dedicated 3D spatial analysis workflow for drug development.

  3. ERC Starting Grant for the SynapTau team

    Maud, Chiara, and Matthew (SynapTau team) are happy to announce the award of an ERC Starting Grant for the team, with the project set to begin in January 2025. The ERC project "SynApoE" aims to characterize how ApoE4 controls synaptic degeneration in Alzheimer's disease.

    We invite you to celebrate this great news on September 23rd, during Maud's HDR celebration.

    We look forward to sharing this moment with you!

  4. NeuroCyto team in Science: the unique architecture of axonal endocytosis

    We’re over the moon to see our latest work with Stéphane Vassilopoulos and his team published in Science. Check out how we reveal the unique architecture of clathrin-coated pits and endocytosis at the axon initial segment!

  5. INP teams attending Canceropole 11th Annual Seminar

    Comme chaque année les équipes 8, 9 et 10 de l’INP ont participé au Séminaire Annuel du Canceropôle qui se tenait au Palais des Congrès de Saint-Raphaël les 4 et 5 juillet 2024.

  6. Chiara received a prize for the best master’s thesis

    Congratulations to Chiara Bordier (team 2 SynapTau) for receiving the GBM (Association for Biochemistry and Molecular Biology) Master Prize for the best master’s thesis! This year, Professor Lichtenthaler from Technische Universität München and the DZNE presented this honour, marking the fourth time it has been awarded. Chiara's award-winning research explored the impact of Tau protein on nuclear organization and chromatin dynamics in neurodegenerative diseases, highlighting its crucial role in nuclear tension and stress response.

  7. INP & VH invited to the "Imagining the futur of cancer treatments" symposium

    INP and Vect-Horus both participated to the symposium “Imagining the future of cancer treatments” (~100 participants) organized by the Translate-It departement of CRCM in Luminy. Along with keynote speaker Maria Kavallaris (Director of the Australian Centre for NanoMedicine at UNSW), François Devred gave an overview of INP's work on cancer entitle "How the INP contributes to the future of cancer treatments" and Pavlo Shpak-Kraievskyi of Vect-Horus gave a talk on "Surface modification of LNPs for brain targeting of nucleic acids"

  8. 3 doctorants de l'INP à la FENS 2024

    Sofia (doctorante équipe 7), Charbel (doctorant équipes 3 et 9) et Jehanne (doctorante équipe 5) ont participé et présenté des posters à FENS 2024 à Vienne (Autriche). Ce fut une expérience enrichissante de discuter de leurs travaux avec leurs pairs, d'assister à des présentations sur des recherches novatrices dans nos domaines respectifs, et de déguster des plats typiques autrichiens avec d'autres membres de NeuroMarseille et d’ailleurs. 

Pages

L'INP en chiffres

  • 126 membres
  • 44 chercheurs
  • 48 chercheurs assistants
  • 12 post-doctorants
  • 11 doctorants

 

GlioME team and PETRA"TECH" platform: a new paper is out in Neuro-Oncology!

Because generation of patient avatar for preclinical therapeutic development is critically needed in neuro-oncology, the GlioME team in collaboration with the PETRA"TECH" platform developed an easy method to generate tumoroids from primary and metastatic brain tumors, including a dedicated 3D spatial analysis workflow for drug development.

Indéfini

ERC Starting Grant for the SynapTau team

Maud, Chiara, and Matthew (SynapTau team) are happy to announce the award of an ERC Starting Grant for the team, with the project set to begin in January 2025. The ERC project "SynApoE" aims to characterize how ApoE4 controls synaptic degeneration in Alzheimer's disease.

We invite you to celebrate this great news on September 23rd, during Maud's HDR celebration.

We look forward to sharing this moment with you!

Indéfini

Chiara received a prize for the best master’s thesis

Congratulations to Chiara Bordier (team 2 SynapTau) for receiving the GBM (Association for Biochemistry and Molecular Biology) Master Prize for the best master’s thesis! This year, Professor Lichtenthaler from Technische Universität München and the DZNE presented this honour, marking the fourth time it has been awarded. Chiara's award-winning research explored the impact of Tau protein on nuclear organization and chromatin dynamics in neurodegenerative diseases, highlighting its crucial role in nuclear tension and stress response.

Indéfini

3 doctorants de l'INP à la FENS 2024

Sofia (doctorante équipe 7), Charbel (doctorant équipes 3 et 9) et Jehanne (doctorante équipe 5) ont participé et présenté des posters à FENS 2024 à Vienne (Autriche). Ce fut une expérience enrichissante de discuter de leurs travaux avec leurs pairs, d'assister à des présentations sur des recherches novatrices dans nos domaines respectifs, et de déguster des plats typiques autrichiens avec d'autres membres de NeuroMarseille et d’ailleurs. 

Français

Agenda

20 sep 2024 14:30

INP external seminar : Anissa Jhumka

Salle 52

Revealing novel signatures of pathological pain through next-generation behavioral sequencing and awake rs-fMRI

 

With symptoms such as spontaneous pain, allodynia and or hyperalgesia, chronic pain affects more than 1.5
billion people worldwide and accounts for about 20% of physician visits. Yet, up to two-thirds of patients are
unsatisfied with current treatments. Despite relentless pharmacological efforts and major scientific advances in
our understanding of how the brain orchestrates coping behavioral mechanisms in response to pathological
pain, this past decade has been marked by an increasing number of failing clinical trials. Interestingly, current
pain behavioral and neuroimaging studies present tremendous potential in terms of translational diagnostic,
prognostic and or treatment-response tools. However, many technical obstacles. First, while humans can
verbally describe their pain, studies on rodents have long relied on behavioral assays providing non-exhaustive
characterization or altering animals’ original sensitivity through repetitive stimulations. Second, the variability
across chronic pain patients and conditions makes it challenging to understand functional brain dynamic
alterations supporting pain chronification or resolution. While pain duration varies according to the initial cause
of tissue injury, there is no rigorously controlled study establishing both semiology- and etiology-specific
dynamic brain signatures for the transition from acute to chronic pain. In line with this, most preclinical pain
neuroimaging studies are performed on anesthetized laboratory animals, which is a confound considering the
analgesic effect of anesthetics. Such caveats render correlations between chronic pain as a disease and inherent
behavioral and real-time brain activity alterations, challenging. Here I present emerging videography and
computational-based behavioral approaches that have the potential to significantly improve preclinical pain
research. Lastly, through a preliminary study, I show how the unprecedented longitudinal coupling of behavior
and awake resting-state fMRI in head-fixed mice, can unravel novel anatomical targets for the treatment of long-
lasting pain.

23 sep 2024 10:00

David BLUM Caffeine and adenosine receptors control multicellular processes leading to memory deficits in Alzheimer’s Disease

Amphi 7 (5e aile rouge ) / Amphi 7 ( 5th floor red section)

Caffeine and adenosine receptors control multicellular processes leading to memory deficits in Alzheimer’s Disease

Epidemiological and experimental studies including ours support the beneficial effect of habitual caffeine consumption in Alzheimer's Disease (AD). The underlying mechanisms remain however ill-defined but are thought to depend on its ability to block adenosine A2A receptors, found upregulated in hippocampal neurons and astrocytes of AD patients. The present seminar will highlight recent data from our group that demonstrate the ability of caffeine to control neuro-glial mechanisms linked to hippocampal memory. Moreover, the multicellular consequences of adenosine receptor upsurge found in the AD brain and unveiled using the combination of transgenic, 3D morphological and transcriptomic approaches, will be discussed together with the subsequent translational developments.

 

 

Partenaires